Back to results
US 10,308,980 B2Granted
Methods and biomarkers for analysis of colorectal cancer
AssigneeOslo Universitetssykehus Hf
InventorsRagnhild A. Lothe, Trude Holmeide Agesen, Anita Sveen, Guro Elisabeth Lind, Arild Nesbakken, Rolf Inge Skotheim
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods and biomarkers (e.g., gene expression biomarkers) for detection of colorectal cancer in biological samples (e.g., tissue samples, biopsy samples, stool samples, blood samples, plasma samples, serum samples). In some embodiments, methods and biomarkers of the present invention find use in detection of colon cancer and in providing a prognosis to colorectal cancer patients.
Claims10
A method for treating a human subject that has stage II colorectal cancer, comprising:
- a) extracting and reverse transcribing mRNA from a tumor sample from a human subject that has stage II colorectal cancer to provide complementary DNA;
- b) detecting the expression level of, SESN1, AZGP1, KLK6, EPHA7, and SEMA3A, mRNA transcripts, wherein said detection comprises contacting said complementary DNA with primers specific for complementary DNAs corresponding to, SESN1, AZGP1, KLK6, EPHA7, and SEMA3A, mRNA transcripts, amplifying said complementary DNAs;
- and quantifying the expression levels of said mRNA transcripts;
- c) determining that said human subject has altered expression of, SESN1, AZGP1, KLK6, EPHA7, and SEMA3A, mRNA transcripts,
- administering adjuvant chemotherapy to said human subject determined to have altered levels of expression of, SESN1, AZGP1, KLK6, EPHA7, and SEMA3A, mRNA transcripts, as compared to reference levels of expression, wherein said reference level is selected from the group consisting of the level in stage I colorectal cancer, the level in non-cancerous colorectal tissue, and the level in pre-cancerous colorectal tissue.
2 more elements
Dependencies are inferred from the claim text.